ORAP Drug Patent Profile
✉ Email this page to a colleague
When do Orap patents expire, and what generic alternatives are available?
Orap is a drug marketed by Teva and Concordia Pharms Inc and is included in three NDAs.
The generic ingredient in ORAP is prednisolone sodium phosphate. There are eighty-eight drug master file entries for this compound. Fifteen suppliers are listed for this compound. Additional details are available on the prednisolone sodium phosphate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Orap
A generic version of ORAP was approved as prednisolone sodium phosphate by BAUSCH AND LOMB on July 29th, 1994.
Summary for ORAP
US Patents: | 0 |
Applicants: | 2 |
NDAs: | 3 |
Raw Ingredient (Bulk) Api Vendors: | 82 |
Patent Applications: | 5,185 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for ORAP |
DailyMed Link: | ORAP at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for ORAP
US Patents and Regulatory Information for ORAP
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Teva | ORAP | pimozide | TABLET;ORAL | 017473-003 | Aug 27, 1997 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Concordia Pharms Inc | ORAPRED ODT | prednisolone sodium phosphate | TABLET, ORALLY DISINTEGRATING;ORAL | 021959-001 | Jun 1, 2006 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Teva | ORAP | pimozide | TABLET;ORAL | 017473-001 | Jul 31, 1984 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |